U.S. markets open in 2 hours 14 minutes
  • S&P Futures

    4,163.75
    +3.75 (+0.09%)
     
  • Dow Futures

    34,154.00
    +36.00 (+0.11%)
     
  • Nasdaq Futures

    13,512.50
    +21.50 (+0.16%)
     
  • Russell 2000 Futures

    2,244.30
    +7.70 (+0.34%)
     
  • Crude Oil

    65.27
    -0.36 (-0.55%)
     
  • Gold

    1,789.90
    +5.60 (+0.31%)
     
  • Silver

    26.74
    +0.22 (+0.82%)
     
  • EUR/USD

    1.2048
    +0.0039 (+0.33%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • Vix

    18.90
    -0.58 (-2.98%)
     
  • GBP/USD

    1.3933
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.0960
    -0.0930 (-0.09%)
     
  • BTC-USD

    57,827.32
    +2,442.63 (+4.41%)
     
  • CMC Crypto 200

    1,481.20
    +75.89 (+5.40%)
     
  • FTSE 100

    7,055.24
    +15.94 (+0.23%)
     
  • Nikkei 225

    29,331.37
    +518.77 (+1.80%)
     

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. By way of example, e-therapeutics (LON:ETX) has seen its share price rise 474% over the last year, delighting many shareholders. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

Given its strong share price performance, we think it's worthwhile for e-therapeutics shareholders to consider whether its cash burn is concerning. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

View our latest analysis for e-therapeutics

When Might e-therapeutics Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at July 2020, e-therapeutics had cash of UK£15m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through UK£3.3m. That means it had a cash runway of about 4.6 years as of July 2020. A runway of this length affords the company the time and space it needs to develop the business. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is e-therapeutics' Cash Burn Changing Over Time?

In the last year, e-therapeutics did book revenue of UK£305k, but its revenue from operations was less, at just UK£305k. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. With the cash burn rate up 36% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can e-therapeutics Raise Cash?

While e-therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

e-therapeutics has a market capitalisation of UK£61m and burnt through UK£3.3m last year, which is 5.4% of the company's market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About e-therapeutics' Cash Burn?

As you can probably tell by now, we're not too worried about e-therapeutics' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, e-therapeutics has 3 warning signs (and 2 which are significant) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.